Of the most senior full time jobs on the career ladder to chief executive, such as divisional or regional heads, only 21% are ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GlobalData on MSN7d
GSK CEO addresses declining trust in vaccines following Trump re-electionGSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...
Representative Image As consumers increasingly prioritize convenience and health-conscious choices, the FMCG sector is swiftly evolving to meet these demands. This shift is reshaping the landscape ...
(Reuters) -Haleon posted an unexpected drop in third-quarter revenue on Thursday, hurt by a weak demand for its painkiller in ...
GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...
Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback